Abbott Finalizes Purchase of Exact Sciences to Expand Cancer Diagnostics

On March 23, 2026, healthcare giant Abbott finalized its acquisition of Exact Sciences for $23 billion, a move set to transform the landscape of cancer diagnostics.

orgAbbott

orgExact Sciences

conceptcancer diagnostic

By acquiring Exact Sciences, Abbott gains access to advanced technologies like the noninvasive Cologuard test and Oncotype DX genomic tests.

orgExact Sciences

orgAbbott

techCologuard

techOncotype DX

This strategic expansion is designed to make Abbott a leader in the high-growth fields of cancer screening and precision oncology, effectively doubling its addressable market in this sector to over $120 billion.

orgAbbott

conceptprecision oncology

Financially, the deal is expected to add roughly $3 billion in incremental sales to Abbott’s 2026 performance, pushing total annual diagnostics sales beyond $12 billion.

orgAbbott

Exact Sciences will operate as a subsidiary based in Madison, Wisconsin, with former CEO Kevin Conroy moving into an advisory position.

orgExact Sciences

locationMadison

locationWisconsin

personKevin Conroy

This major transaction highlights Abbott's commitment to shifting its portfolio toward predictive and personalized medicine, solidifying its role at the forefront of modern medical innovation.

orgAbbott

conceptpersonalized medicine

🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary strategic goal of Abbott's acquisition of Exact Sciences?

To become a global leader in cancer screening and precision oncology.

To divest from its current diagnostics business units.

To increase its dominance in the consumer electronics sector.

Reveal Answer

✓

Correct Choice

To become a global leader in cancer screening and precision oncology.

What is the total enterprise value of the deal?

Approximately $12 billion.

Approximately $3 billion.

Roughly $23 billion.

Reveal Answer

✓

Correct Choice

Roughly $23 billion.

Which technology is mentioned as part of the acquisition portfolio?

Cardiovascular surgical robots.

Cologuard, a noninvasive colorectal cancer screening test.

Diabetes insulin monitoring systems.

Reveal Answer

✓

Correct Choice

Cologuard, a noninvasive colorectal cancer screening test.

How will the acquisition affect Exact Sciences' operational location?

All operations will be moved to international laboratories.

It will remain in Madison, Wisconsin.

The company will relocate its headquarters to Abbott's home office.

Reveal Answer

✓

Correct Choice

It will remain in Madison, Wisconsin.

What is the expected impact on Abbott's 2026 earnings per share?

A dilution of approximately $0.20 per share.

An increase of $0.20 per share.

No change to the earnings per share.

Reveal Answer

✓

Correct Choice

A dilution of approximately $0.20 per share.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play